Skip to main content

Table 2 Toxicities of the h-R3/RT and CDDP/RT groups (N = 104)

From: A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma

Toxicities (RTOG Grade) h-R3/RT (N = 52) [n (%)] CDDP/RT (N = 52) [n (%)] P Value*
WBC    0.048*
 (1&2) 32 (61.5%) 32 (61.5%)  
 (3&4) 1 (1.9%) 7 (13.5%)  
PLT    0.752
 (1&2) 19 (36.5%) 18 (34.6%)  
 (3&4) 1 (1.9%) 2 (3.8%)  
HB    0.499
 (1&2) 27 (51.9%) 26 (50%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
ALT    0.294
 (1&2) 10 (19.1%) 8 (11.9%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
AST    0.197
 (1&2) 10 (19.2%) 5 (9.6%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
GGT    0.166
 (1&2) 9 (17.3%) 5 (9.6%)  
 (3&4) 0 (0.00%) 0 (0.00%)  
Dermatitis    0.445
 (1&2) 33 (63.5%) 44 (84.6%)  
 (3&4) 2 (3.8%) 1 (1.9%)  
Rash    0.248
 (1&2) 5 (9.6%) 3 (5.8%)  
 (3&4) 1 (1.9%) 0 (0.00%)  
Mucositis    0.093
 (1&2) 21 (40.4%) 26 (50%)  
 (3&4) 30 (57.7%) 25 (48.1%)  
Taste change    0.763
 yes 46 (88.5%) 47 (90.4%)  
 no 6 (11.5%) 5 (9.6%)  
Vomit    0.000*
 only nausea 12 (23.1%) 2 (3.8%)  
 nausea and vomit 5 (9.6%) 43 (78.8%)  
Weight loss    0.249
 (1&2) 26 (50.0%) 30 (57.7%)  
 (3&4) 13 (25.0%) 15 (28.8%)  
  1. Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy. WBC white blood cell, PLT Platelets, HB hemoglobin, ALT alanine transaminase, AST glutamic-oxalacetic transaminease, GGT gamma glutamyl transpeptidase
  2. *All p values were obtained by the paired rank sum test